DalsnaFinance

STARMED Receives FDA 510(k) Clearance for a Benign Thyroid Nodule Ablation Indication

Markets PR Newswire By PR Newswire 01 Jul 2026 12:00 1 min read
STARMED Receives FDA 510(k) Clearance for a Benign Thyroid Nodule Ablation Indication

SEOUL, South Korea, July 1, 2026 /PRNewswire/ -- STARMED, a medical device company specialising in minimally invasive treatment technologies, has announced that it has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for a thyroid-specific indication (510(k)...

SEOUL, South Korea, July 1, 2026 /PRNewswire/ -- STARMED, a medical device company specialising in minimally invasive treatment technologies, has announced that it has obtained 510(k) clearance from the US Food and Drug Administration (FDA) for a thyroid-specific indication (510(k)...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.